NPS Pharmaceuticals (NPSP) On Watch With FDA Briefing Documents Posted
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
NPS Pharma (NPSP) Halted Ahead of FDA Committee Meeting for Gattex
October 16, 2012 7:11 AM EDTNPS Pharmaceuticals, Inc. (NASDAQ: NPSP) shares were halted ahead of the Gastrointestinal Drugs Advisory Committee meeting to review Gattex (teduglutide). The meeting is scheduled for today, October 16, 2012 at 8:00 a.m. ET.
The briefing materials can be found on the FDA website at... More
